Vertical: HCBase Year: 2018
Market Size (2018)
$6.90B
Projected (2025)
$24.71B
CAGR (2016–2025)
22.4%
Key Players
3+
Artificial retina is a minimally invasive device used to treat vision problems such as age-related macular degeneration and retinitis pigmentosa. The artificial retina implanted into the eye receives signals from the small camera located on the eyeglasses and wirelessly sends signals to the microprocessor to create an image that the patient can see clearly.
Factors such as rapid growth in the geriatric population with vision problems, product launch and technological advancement in artificial retina products, and the growing population with retinitis pigmentosa diseases, are driving the growth of the artificial retina market. However, surgical complications of artificial implants and the availability of alternative treatment methods are hampering the market growth.
The Artificial Retina Market market is projected to grow at a CAGR of 22.4% from 2016 to 2025.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe scope of the global artificial retina market study includes market size analysis and a detailed analysis of the manufacturer’s products and strategies. The market has been segmented based on type, indication, end user, and region.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2018
Historical Period
2016 – 2017
Forecast Period
2019 – 2025
Primary Interviews
150+
Historical data (2016–2018) and forecast period (2018–2025)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe global artificial retina market is expected to be a very lucrative, attractive, and profitable market, both for existing as well as new entrants. At the same time, intense rivalry among existing competitors has been observed. Our analysis revealed that key market players have adopted different strategies to increase their business and position in the global artificial retina market. In recent years, strategies such as product launches, agreements, and approvals, were adopted by key players to reduce competition and generate market growth. The major players in the global artificial retina market are Second Sight, Pixium Vision, and Optobionics.
Companies are entering into distribution agreements with big players in the healthcare industry to neutralize growing competition from customers, competitors, and to tackle the changing market dynamics.
A few key players are operating in this market globally. Mostly, these players exist in the Americas and Europe. Owing to the limited players in the market, the market shares are marginally differentiated. Second Sight is the top player in the global artificial retina market. It is the only company whose product is FDA approved. Pixium Vision’s Prima Bionic Vision System is undergoing human clinical trials and is expected to be launched in the upcoming years.
Bargaining Power of Suppliers
The bargaining power of suppliers in the artificial retina market is expected to be high. The number of raw material suppliers in the market is low, which limits the options for the market players. On the other hand, since high-quality materials are used in the manufacturing of artificial retina devices, only a few numbers of viable raw material suppliers are available, which further increases the bargaining power of suppliers in the market.
Bargaining Power of Buyers
The bargaining power of buyers is low in the artificial retina market. The market has a large number of buyers that are ophthalmic centers, hospitals, and individual professionals. On the other hand, the number of manufacturers is very low, due to which the buyers have limited options in the market. This decreases the bargaining power of buyers in the global artificial retina market.
Threat of New Entrants
The threat of new entrants is expected to be high in the artificial retina market. The new participants planning to enter the market are required to abide by the mandatory regulatory standards in the manufacturing of the artificial retina devices. Also, the market is characterized by brand loyalty, where establishing a brand name is difficult for the new entrants. However, the presence of very few players in the market offers lucrative opportunities for players to enter the market, which increases the threat of new entrants.
Threat of Substitutes
The threat of substitutes in the global artificial retina market is expected to be low as there are no relative substitutes available for the artificial retina.
Intensity of Rivalry
The degree of competition in the artificial retina market is medium. The modest degree of product differentiation among existing few players increases the intensity of rivalry in the market slightly. The company’s manufacturing artificial retina devices are working on developing cost-effective products, especially for use in developing countries. Moreover, the players are also developing advanced technology implants for differentiating their products.
Market estimates by geography (2025)
InsightAmericas leads with $11.87B by 2025.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2016 | 2018 | 2025 | CAGR | SHARE |
|---|---|---|---|---|---|
| Middle East and Africa | $285.55M | $439.53M | $1.19B | 17.2% | 5% |
| Americas | $1.15B | $4.31B | $11.87B | 29.6% | 48% |
| Asia Pacific | $754.26M | $1.87B | $5.21B | 27.3% | 21% |
| Europe | $2.59B | $2.30B | $6.44B | 10.7% | 26% |
| Total | $4.78B | $8.92B | $24.71B | 22.4% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$24.71B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Epiretinal Implants | $19.57B | 19.2% | 79% |
| Subretinal Implants | $4.73B | 54.3% | 19% |
| Suprachoroidal Implants | $411.56M | 55.8% | 2% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Artificial Retina Market covering market dynamics, competitive landscape, and strategic outlook.
The Artificial Retina Market market is projected to reach $24.71B by 2025, growing at 22.4% CAGR. The Epiretinal Implants segment holds the largest share.
Artificial retina implant is a bioelectric device which includes microelectronics and microchip electrodes that are surgically placed into the back of the eye to restore the function of damaged light cells (rods and corns). Artificial retina devices thus bypass defected photoreceptor cells and pass electrical signals directly to the retina and optical nerves which help patients in creating a visual image.
Factors such as growing geriatric population, which leads to age-related vision problems, an increasing number of people affected by retinitis pigmentosa diseases and increasing investment and research activities to develop eye care products drive the market growth. Additionally, the growing prevalence of diabetes causes vision problems boosting market growth. However, surgical complications of artificial implants and the presence of alternative treatment methods hamper market growth.
Likewise, the development of innovative products would serve as an opportunity for market growth.
The aging population is highly prone to degenerative diseases and eye problems, which eventually leads to a rise in diagnosis and treatment. Age-related macular degeneration (ARMD) also known as macular degeneration, is one of the serious eye diseases that may cause permanent vision loss in people above the age of 60. ARMD occurs when the retina gets damaged and the patient could not see clearly. The person having ARMD could get blurry images and faces difficulty in differentiating color. According to the National Center for Biotechnology Information, 2016 the prevalence of ARMD in the US is anticipated to increase to 22 million by 2050, and the global prevalence is expected to rise to 288 million by 2040.
Additionally, according to the BrightFocus Foundation fact sheet, 11 million people in the US has some form of age-related macular degeneration and it is expected to get double to nearly 22 million by 2050. Furthermore, BrightFocus Foundation reported that the estimated cost of visual loss due to ARMD in the US, Cuba, and Canada collectively is approximately USD 98 billion. The increasing spending on vision impairment treatment drives market growth.
Also, the rising aging population will lead to an increase in ARMD cases, which will eventually lead to growth in the artificial retina market.
The artificial retina itself is a new approach and an upcoming technology in the healthcare industry. There are various companies involved in developing a bionic eye as a treatment option for patients with vision problems. There are continuous funding and research support from various research organizations to develop these products. For instance, in August 2018, the American Chemical Society, a leading scientific society with more than 152,000 members in 120 countries, developed a new generation of artificial retina based on 2D material. Scientists from these organizations have developed ultrathin artificial retina using molybdenum disulfide and graphene as well as thin layers alumina, gold, and silicon nitrate to create a flexible, high-density and curved sensor array. Similarly, there are various other research organizations involved in developing these types of vision care products.
Hence, the rising need for the treatment of vision problems and increasing research activities act as an opportunity for the growth of the market.
Irrespective of innovative technology for the eye treatment artificial retina has some postoperative complications. Artificial retina involves the surgical process in which an electronic chip is implanted on the retina which causes eye problems. Post-operative complications include inflammation of intraocular fluids, conjunctival erosion, infection to the retina, and stimulation of nearby nerve cells as a side-effect. Additionally, patients suffering from glaucoma disease are not suitable for this product as it requires normal functioning optic nerve cells to receive signals.
Some of the other issues with electrical stimulation of the retina are that the electrodes need to be as small as possible only to stimulate a few nerve cells. These types of problems may lead to poor resolution and hamper market growth.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 103 companies operating in the Artificial Retina Market market, including revenue, employee count, and market positioning where available.
Showing 103 of 103 companies
Company Headquarters: California, US Founded: 1998 Workforce: ~123+ Company Working: Second Sight develops, manufactures, and markets prosthetic devices used as a treatment for blind individuals. Its principal office is in California, US. The company also has an office in Switzerland, which manages clinical and commercial operations in Europe, Asia, and the Middle East. It sells its products across Europe, Saudi Arabia, the US, Canada, Turkey, Iran, Taiwan, South Korea, Russia, and Singapore.
Company Headquarters: France Founded: 2011 Workforce: ~30+ Company Working: Pixium Vision is a bioelectronics and brain-machine interface technology company. It connects rapid advances in visual processing, microelectronics, optoelectronics, neurobiology, and intelligent software algorithms to develop Bionic Vision Systems that utilize its competencies in machine brain interface and artificial intelligence. The company is supported by various international and multidisciplinary scientific advisory boards and partners, such as the National Health Service, Inserm, Moorfields Eye Hospital, Institut De La Vision, and The French National Center for Scientific Research (CNRS), among others.
Company Headquarters: Illinois, US Company Working: Optobionics is the manufacturer of the Artificial Silicon Retina microchip (ASR). The chip was invented to stimulate damaged retinal cells from within the retina to allow the cells to recreate visual signals that are processed and sent to the brain. The device can be used in the treatment of retinitis pigmentosa.
Coty is a fragrance-led global beauty company and, by its own description, one of the world's largest beauty groups, with FY2026 net revenues of USD 5.81bn split roughly two-thirds Prestige (licensed and owned luxury fragrance, prestige cosmetics and skincare — Burberry, Hugo Boss, Calvin Klein, Chloé, Marc Jacobs, Davidoff, Kylie Cosmetics, Gucci until mid-2027) and one-third Consumer Beauty (mass color cosmetics such as CoverGirl, Rimmel, Max Factor and Sally Hansen; mass fragrance; and Brazilian body care). Its core competitive asset is an end-to-end fragrance platform — licensing, innovation, ~81% in-house manufacturing and global prestige distribution — that has produced blockbuster franchises such as Burberry Goddess. After five years of deleveraging under Sue Nabi, Coty entered 2026 in a reset: revenue and margins are declining, the Gucci licence exits a year early, mass color and Brazil are under strategic review, and new interim leadership is executing a "Coty.Curated" focus-and-simplify framework with leverage of 3.4x. --- **Company's own description (paraphrased from FY2026 10-K, Item 1).** Coty describes itself as one of the world's largest beauty companies with an iconic brand portfolio across fragrance, color cosmetics, and skin and body care. It states that it is focused on leveraging its leadership position and capabilities in global fragrances to fuel expansion, strengthening its presence in a limited number of structurally profitable and growing categories, and prioritising growth channels such as e-commerce and Travel Retail. Under the Coty.Curated framework it emphasises fewer, bigger initiatives, marketing sufficiency, supply reliability, consumer advocacy, more productive innovation and portfolio choices, a return to market-share growth, and AI-powered, data-driven operations. It is also evaluating its central organisation, manufacturing and asset base to resize after the Gucci exit. **What the company does.** Coty designs, manufactures (≈81% in-house, ≈19% via third-party manufacturers in FY2026), markets and distributes beauty products. The essential oils in its fragrances are generally sourced from specialist fragrance houses; Coty owns the brand development, juice selection/briefing, bottle and packaging design, filling and assembly, marketing and commercial execution. Principal raw materials are essential oils, alcohols and specialty chemicals (10-K FY2026). **Business model and revenue model.** **Value-chain position.** Coty sits between ingredient suppliers (fragrance houses, alcohol and packaging suppliers) and retailers. Its economic moat lies in (i) licence portfolio scale in prestige fragrance, (ii) innovation and launch capability (brief-to-shelf), and (iii) owned manufacturing in the U.S., Europe and Brazil. It is structurally exposed to licensors (who own the trademarks) and to concentrated retailers (Sephora, Ulta, Douglas, Walmart, drug chains, travel-retail operators). **End markets.** Prestige fragrance (core), prestige cosmetics (Kylie Cosmetics, Marc Jacobs Beauty, Gucci Beauty until FY2027), prestige skincare (Lancaster, philosophy), mass color cosmetics, mass fragrance and mists, mass skin & body care (concentrated in Brazil). **Independent characterisation.** Coty is effectively two businesses with very different economics: a high-quality, licence-dependent prestige fragrance franchise generating ~20% adjusted EBITDA margins (Prestige FY2026 adjusted EBITDA margin 20.5% per Q4 FY2026 call), and a structurally challenged mass color cosmetics/Brazil business whose segment adjusted EBITDA margin collapsed to the low single digits in FY2026 (derived). The 2025–2026 strategic actions (Wella exit, Gucci monetisation, Consumer Beauty review) are converting Coty into a narrower fragrance pure-play with lower leverage but higher licence concentration.
Codexis is a Redwood City-based enzyme engineering company in the middle of a deliberate transition. It is moving from a diversified "protein engineering" platform company, whose revenue was historically dominated by custom biocatalysts for small-molecule drug manufacturing, toward a focused provider of enzymatic manufacturing solutions for oligonucleotide therapeutics, chiefly siRNA/RNAi. Its proprietary CodeEvolver® directed-evolution platform underpins two businesses. The first is a cash-generating but lumpy pharma biocatalysis franchise, anchored by long-standing relationships with Merck & Co. and other large pharmaceutical companies, which supports about 14 commercial products. The second is the pre-commercial ECO Synthesis® Manufacturing Platform, which aims to replace solid-phase phosphoramidite chemistry with enzymatic routes, together with a commercially launched dsRNA ligase. The company is a sub-$200 million market capitalization micro-cap and remains loss-making. It has about $80 million of pro forma liquidity, a $40 million term loan, and guidance for FY2026 revenue of $72–76 million. --- ### Company's own description (FY2025 10-K / standard press-release boilerplate, paraphrased) Codexis describes itself as a leading provider of enzymatic solutions for efficient, scalable therapeutics manufacturing. It discovers, develops and improves high-performance enzymes using its proprietary CodeEvolver® technology. According to the company, its enzymes address real-world problems in small-molecule pharmaceutical manufacturing and nucleic acid synthesis. Codexis is developing the ECO Synthesis® Manufacturing Platform to enable scaled manufacture of RNAi therapeutics through an enzymatic route. It says its enzymes can raise yields, cut energy use and waste, improve manufacturing efficiency, and increase sensitivity in genomic and diagnostic applications (Codexis Q4 FY2025 and Q2 FY2026 press releases). The FY2025 10-K states that headquarters is both the administrative centre and the centre of research, development and business operations, with limited internal manufacturing capacity. In-house manufacturing produces Codex® biocatalyst panels and kits, plus enzymes for customers' pilot-scale and clinical production. The ECO Synthesis Innovation Lab sits inside headquarters and is designed to supply non-GMP material in quantities that support customers' preclinical development. The company expects to partner with CDMOs for bulk GMP-grade siRNA production for clinical supply and beyond. ### Independent characterization Codexis is best understood as a technology-licensing and specialty-enzyme supplier whose economics depend on a small number of very large pharmaceutical relationships. In FY2025 a single customer accounted for about 51% of total revenue (FY2025 10-K, "Customers"). Given the $37.8 million Merck agreement recognised mainly in Q4 FY2025, that customer is almost certainly Merck. The business model has three monetization layers. The first layer is product revenue: sales of engineered enzymes (biocatalysts), pharmaceutical intermediates, Codex® biocatalyst screening panels and kits, and, increasingly, ligase and ECO enzyme supply. Product revenue is driven by customers' commercial manufacturing schedules and is therefore volatile quarter to quarter. Product gross margin has improved structurally, from 56% in FY2024 to 64% in FY2025 and 71–73% in Q1–Q2 FY2026. Management attributes this to a shift toward higher-margin products and the run-off of lower-margin legacy products. The second layer is research and development revenue: CodeEvolver platform licence fees, technology-transfer payments, milestone payments, feasibility and evaluation fees, and ECO Synthesis manufacturing services (for example, the low-seven-figure contract to supply 50 g of siRNA). In FY2025 R&D revenue exceeded product revenue for the first time in the period analysed ($44.4 million vs. $26.0 million). The main reason was the Merck technology transfer. The third layer is royalty and contingent consideration from out-licensed or divested assets. These include the Nestlé Health Science CDX-7108 sale (up to $45 million in milestones plus a single-digit royalty), the Aldevron HiCap RNA polymerase licence (milestones and royalties), and the Roche dsDNA ligase licence (upfront and technical milestones). These are largely back-ended and uncertain. **Value-chain position.** Codexis sits upstream of drug-substance manufacturing. It supplies process technology (enzymes and the know-how to use them) to innovator pharma companies, generic manufacturers and CDMOs, which then run the commercial processes. In the oligonucleotide chain it is trying to move one step downstream. Its planned ECO GMP Manufacturing Center would make siRNA material for preclinical and Phase 1 supply. This hybrid "tool supplier plus early-phase manufacturer" model is a new risk profile for the company. **Customer types:** large innovator pharma (Merck, plus historically Pfizer, GSK and Novartis); high-growth RNAi biotech innovators (unnamed counterparties in 2025–2026 agreements); CDMOs (Bachem, Nitto Denko Avecia, Axolabs); and life-science tools companies (Roche, Aldevron, seqWell). **End-markets served:** small-molecule API manufacturing (biocatalysis); oligonucleotide/RNAi therapeutic manufacturing; and, as a residual licensing stream, life-science tools and genomics reagents. ### Revenue model mix (FY2021–FY2025) *Sources: Q4 FY2022 press release (FY2021–FY2022 PAXLOVID figures); FY2023 10-K (product revenue); Q4 FY2023 press release (ex-PAXLOVID revenue of $62.0 million implies about $8.1 million PAXLOVID-related revenue in FY2023, largely the release of deferred Pfizer fees); Q4 FY2025 8-K Exhibit 99.1 (FY2024–FY2025). Shares are computed.*
Eli Lilly is a research-based, vertically integrated pharmaceutical manufacturer that discovers, develops, manufactures and markets prescription medicines in a single reported business segment: human pharmaceutical products. Its commercial identity has been transformed since 2022 by the incretin class: tirzepatide, a dual GIP/GLP-1 receptor agonist, and from April 2026 orforglipron, an orally bioavailable non-peptide GLP-1 agonist. These assets have made Lilly the dominant player in the fastest-growing therapeutic category in pharmaceutical history, and have funded a step-change in capital deployment — more than $50 billion of announced U.S. manufacturing investment since 2020, $13.3 billion of FY2025 R&D spend, and more than a dozen acquisitions in 2026 alone. Around that core the company sustains four other franchises — oncology, immunology, neuroscience and legacy diabetes — and a direct-to-patient platform, LillyDirect. Lilly's central strategic bet is that obesity becomes a chronic-care category of unprecedented scale, and that it can own the supply, the pricing architecture and the next three generations of molecules within it. Eli Lilly and Company is, as of September 2026, the largest pharmaceutical company in the world by market capitalisation and the fastest-growing large-cap drug manufacturer by revenue. The company crossed the $1 trillion market-capitalisation threshold during 2025 — the first biopharmaceutical company ever to do so — on the strength of a single molecule, tirzepatide, commercialised under two brands (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnoea) that together generated $36.5 billion of revenue in FY2025. In April 2026 the company added the first small-molecule oral GLP-1 receptor agonist approved for obesity, Foundayo (orforglipron), to that franchise. --- ### The company's own characterisation Lilly describes itself in the FY2025 Form 10-K as a company that discovers, develops, manufactures and markets products in a single business segment — human pharmaceutical products — and states that most of the products it sells today were discovered or developed by its own scientists, with long-term success depending on the ability to continually discover or acquire, develop and commercialise innovative medicines. It manufactures and distributes through facilities in the United States (including Puerto Rico) and in Europe and Asia, and sells in approximately 105 countries. In its standard corporate boilerplate (Q2 2026 earnings release) Lilly positions itself as "a medicine company turning science into healing," with a 150-year history and scientific focus areas described as redefining diabetes care; treating obesity and curtailing its long-term complications; advancing the fight against Alzheimer's disease; addressing immune system disorders; and transforming difficult-to-treat cancers into manageable diseases. ### Independent characterisation Lilly is best understood today as three overlapping businesses operating under one P&L: **(a) The incretin platform (roughly 74% of FY2025 revenue).** Tirzepatide (Mounjaro + Zepbound) alone contributed $36.5 billion in FY2025, growing to a first-half 2026 run-rate of $27.7 billion across the two brands. Adding orforglipron (Foundayo, $98 million in its first partial quarter), legacy insulins, Trulicity and the Boehringer-partnered SGLT2/DPP-4 products, cardiometabolic health accounted for approximately $48.2 billion of FY2025 revenue. This is a volume business with unusually strong operating leverage: gross margin on the incretin portfolio has driven consolidated gross margin from 75.4% in FY2021 to 86.3% (non-GAAP) in Q2 2026, even as realised prices fell 13% year-on-year in that quarter. **(b) The diversified specialty portfolio (roughly 24% of FY2025 revenue).** Oncology ($9.4 billion), immunology ($5.2 billion) and neuroscience ($1.4 billion) constitute a conventional branded-pharma business with a normal mix of growth assets (Jaypirca, Ebglyss, Omvoh, Kisunla, Inluriyo) and mature or declining ones (Cyramza, Emgality, Taltz, Olumiant). Management has explicitly flagged this cluster as its diversification hedge: key-product revenue in immunology, oncology and neuroscience grew 121% year-on-year in Q2 2026. **(c) A capital-deployment engine.** With $16.8 billion of FY2025 operating cash flow rising to a $28.1 billion trailing-twelve-month figure at June 2026, Lilly has become one of the most acquisitive companies in the sector — at least thirteen acquisitions announced in 2026 through August — and the largest single builder of pharmaceutical manufacturing capacity in U.S. history. ### Revenue model and value-chain position Lilly's revenue is overwhelmingly product revenue. Approximately 93.5% of FY2025 revenue was product sales, with the balance (approximately $4.2 billion) collaboration and other revenue, principally from the Boehringer Ingelheim diabetes alliance, the Incyte relationship on Olumiant, royalty streams and sales-based milestones. There is no subscription revenue; "service" revenue is immaterial. The company occupies an unusually deep position in its value chain for a modern large-cap pharma: it manufactures its own active pharmaceutical ingredients, fills and finishes its own injectable devices, and, since January 2024, sells directly to patients through LillyDirect, bypassing parts of the traditional wholesaler-pharmacy-PBM chain for self-pay volumes. **Customer types and end-markets.** The direct customers are wholesalers and distributors (McKesson, Cencora, Cardinal Health in the U.S.), retail and specialty pharmacy chains, hospital systems, government purchasers (Medicare Part D plans, Medicaid programs, the Veterans Health Administration, and from 2026 the TrumpRx platform), managed-care organisations and pharmacy benefit managers, and — increasingly — patients paying cash through LillyDirect and affiliated telehealth partners. End-markets are obesity and metabolic disease, type 2 diabetes, oncology, immunology/inflammation, neurodegeneration and pain.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Mn)
